Przeglądaj według tematu "NSCLC"

Wyświetlanie pozycji 1-3 z 3

    • Gut microbial predictors of firstline immunotherapy efficacy in advanced NSCLC patients 

      Grenda, Anna; Iwan, Ewelina; Kuźnar-Kamińska, Barbara; Bomba, Arkadiusz; Bielińska, Katarzyna; Krawczyk, Paweł; Chmielewska, Izabela; Frąk, Małgorzata; Szczyrek, Michał; Rolska-Kopińska, Anna; Jankowski, Tomasz; Kieszko, Robert; Milanowski, Janusz (Nature, 2025)
      The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed to evaluate ...

    • Gut resistome of NSCLC patients treated with immunotherapy 

      Iwan, Ewelina; Grenda, Anna; Bomba, Arkadiusz; Bielińska, Katarzyna; Wasyl, Dariusz; Kieszko, Robert; Rolska-Kopińska, Anna; Chmielewska, Izabela; Krawczyk, Paweł; Rybczyńska-Tkaczyk, Kamila; Olejnik, Małgorzata; Milanowski, Janusz (Frontiers, 2024)
      Background: The newest method of treatment for patients with NSCLC (non-small cell lung cancer) is immunotherapy directed at the immune checkpoints PD-1 (Programmed Cell Death 1) and PD-L1 (Programmed Cell Death Ligand 1). ...

    • Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer 

      Grenda, Anna; Iwan, Ewelina; Chmielewska, Izabela; Krawczyk, Paweł; Giza, Aleksandra; Bomba, Arkadiusz; Frąk, Małgorzata; Rolska, Anna; Szczyrek, Michał; Kieszko, Robert; Kucharczyk, Tomasz; Jarosz, Bożena; Wasyl, Dariusz; Milanowski, Janusz (Springer Open Journal, 2022)
      The significance of Akkermansia bacteria presence in gut micobiome, mainly Akkermansia mucinifila, is currently being investigated in the context of supporting therapy and marker for response to immunotherapy in cancer ...